Fig. 2

On target inhibition and apoptotic cell death induction by adagrasib and abemaciclib combinatorial treatment. A, B, Immunoblot analysis showing dose dependent effects of adagrasib (3 h exposure) on p-ERK in SW1573 cells A and H2122 cells B. C, D, Immunoblot analysis showing time dependent effects of indicated doses of adagrasib on p-ERK in SW1573 cells C and H2122 cells D. E, F, Immunoblot analysis showing dose dependent effects of abemaciclib (24 h exposure) on p-Rb in SW1573 cells E and H2122 cells F. G, Immunoblot analysis of SW1573 cells treated for 48 h with control, 1,000 nM adagrasib, 1,000 nM abemaciclib, and combination therapy. H, Immunoblot analysis of H2122 cells treated for 48 h with control, 100 nM adagrasib, 600 nM abemaciclib, and combination therapy. I, J, Cell cycle analysis in SW1573 and H2122 cells performed with the 4 groups: Control, Adagrasib, Abemaciclib and combination, for 24 h drug exposure at the indicated concentrations. Dean-Jett-Fox model analysis was used for G1, S, G2 cell cycle phase identification. Statistical analysis was with 2-way ANOVA multiple comparison between different groups phases using cell counts (%) after treatments: ^*, Padj < 0.05;^**, Padj < 0.005;^***, Padj < 0.0005; ^****, Padj < 0.00005. K, Caspase 3/7 activity in SW1573 cells treated for 48 h with control, 1,000 nM adagrasib (Ada), 1,000 nM abemaciclib (Abema), and combination therapy. L, Caspase 3/7activity in H2122 cells treated for 48 h with control, 50 nM adagrasib (Ada), 600 nM abemaciclib (Abema), and combination therapy